

Our Mission

The mission of Friends of FSH Research is to accelerate the discoveries that will lead to treatments or cures for FSH Muscular Dystrophy



Our Vision

That one day when FSH Muscular Dystrophy is diagnosed, the next words said are... "there is a treatment!"


2022-23 Annual Report

June 1, 2022 - May 31, 2023

Friends Funds a Record \$770,000 in Research Grants!

Total Research Investment Since 2005 Exceeds \$7,100,000

In the 2022-23 fiscal year, Friends of FSH Research invested over \$770,000 in 6 research projects including grants totaling \$239,000 to The Fred Hutch Cancer Center and \$167,500 to Seattle Children's Hospital, as well as large grants to the University of Kansas, King's College in London, and others. This is the largest amount of grants we've funded in a single year, and brings our total research funding since 2005 to over \$7,100,000!



Thank you to all our sponsors and donors for choosing to invest with us to help improve the lives of those living with FSHD – a disease that slowly destroys skeletal muscles in over half a million women and men around the world.

2022-23 Financial Summary

June 1, 2022 to May 31, 2023


In the fiscal year ending May 31, 2023, Friends of FSH Research:

- Invested a record \$771,742 in 6 FSHD research projects in pursuit of a treatment or cure
- Continued our support of novel research projects that may speed discoveries
- Continued our support of the FSHD Clinical Trials Research Network and future clinical trials

Thanks to the support of our sponsors and donors, the future is looking bright, bringing more hope than ever that a therapy is close at hand for families living with the debilitating effects of FSHD.


2022-23 Revenue - \$826,522

- Auction - \$506,821
- Individuals & Foundations - \$159,031
- Corporate Sponsors - \$128,913
- Matching Funds - \$14,832
- Other - \$16,925



2022-23 Expenses - \$857,939

- Research Projects - \$771,742
- Fundraising (\$83,497) & Administrative (\$2,700)



Balance Sheet as of May 31, 2023

Year-End Assets	\$626,784
Year-End Liabilities	<u>\$508,670¹</u>
Net Assets	\$118,114

¹Funds committed to multi-year research projects that are currently underway

Board of Directors

Terry Colella – President
Rick Colella – Treasurer
Premi Haynes
Erik Svenson

Brad Bagshaw – Vice President
Lynn Fischer
Elizabeth Jas
Karl Voss

George Shaw – Secretary
Chris Haven
Amanda Rickard

Scientific Advisory Board

Jeffrey S. Chamberlain, PhD – Director
Silvere M. van der Maarel, PhD
Gregory J. Block, MSc, PhD
Premi Haynes, PhD

Brian K. Kennedy, PhD
Dennis W. Shaw, MD
Bruce M. Wentworth, PhD

Amanda Rickard, BS
Rabi Tawil, MD
Kyoko Yokomori, PhD